📰 Primary Endpoint News
Page 4 - Primary Endpoint News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Primary Endpoint. Real-time updates on events, politics, business and more.
March 1, 2023
Fourth-Quarter 2022 Results: -- Net Sales of $942.0 Million -- -- GAAP Net Income of $120.4 Million; Adjusted EBITDA of $357.5 Million; Includes $37.3 Million of Acquired IPR&D and Milestones Expenses
March 1, 2023
01.03.2023 - - Achieved $31.3 Million in Net Revenue from Sales of COSELA (trilaciclib) for Full Year 2022, Representing 182% Growth Over 2021; Provided 2023 Net COSELA Revenue Guidance of $50 to $60 Million - - Announced Top Line Results from Pivotal Phase 3 ...
January 3, 2023
—CM-101 Met Primary Endpoint of Safety and Tolerability and Showed Positive Activity Across Multiple Liver Fibrosis Biomarkers and Physiologic Assessments— TEL AVIV, Israel, Jan. 3, 2023... | January 3, 2023
December 29, 2022
TG Therapeutics Announces FDA Approval of BRIUMVI™ (ublituximab-xiiy) - read this article along with other careers information, tips and advice on BioSpace
December 28, 2022
BRIUMVI is the first and only anti-CD20 monoclonal antibody approved for patients with relapsing forms of multiple sclerosis that can be administered in a...
December 2, 2022
DJ Kintor Pharma Announced the Primary Endpoint of Phase II Clinical Study for KX-826's Treatment of Female Androgenetic Alopecia in China Was Met EQS Newswire / 02/12/2022 / 10:34 UTC+8 Kintor
November 7, 2022
Intercept Announces Two Analyses Demonstrating Improvement in Outcomes, Including Transplant-Free Survival, for PBC Patients Treated with OCA to be Presented at AASLD The Liver Meeting® 2022 - read this article along with other careers information, tips and advice on BioSpace
November 7, 2022
Very low LDL-C Levels Data Reinforces Long-Term Efficacy and Consistent Safety Profile of Repatha Observed in FOURIER-OLE THOUSAND OAKS, Calif., N...
November 6, 2022
Efficacy of OCA vs. placebo and external controls accepted as a late-breaker poster HEROES-US data to be presented in oral session on Sunday, November 6  ...
October 6, 2022
ADX-2191 Statistically Superior to Historical Control for Primary Endpoint of Prevention of Retinal Detachment (P=0.024)Numerical Superiority of ADX-2191 over Routine Surgical Care Achieved for Majority of Secondary, Exploratory, and Safety EndpointsADX-2191 Observed to be Well Tolerated with No Safety Concerns Note...